• Publications
  • Influence
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
TLDR
Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulked surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study.
Adjuvant radiotherapy for stage I endometrial cancer.
TLDR
EBRT did not improve survival outcomes in either the intermediate-risk or high- Risk subgroups, although high- risk data were limited, and a benefit of EBRT for high-risk women could not be excluded.
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.
TLDR
The results of this meta-analysis provide the most reliable estimates of the relative survival benefits of IP over IV therapy and should be used as part of this decision making process.
Vaginal dilator therapy for women receiving pelvic radiotherapy.
TLDR
There is no reliable evidence to show that routine regular vaginal dilation during or after radiotherapy prevents the late effects of radiotherapy or improves quality of life and some women may benefit from dilation therapy once inflammation has settled.
Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis.
TLDR
EBRT reduces the risk of locoregional recurrence but has no statistically significant impact on cancer-related deaths or OS, however, EBRT is associated with clinically and statistically significant morbidity and a reduction in quality of life.
Adjuvant chemotherapy for endometrial cancer after hysterectomy.
TLDR
Postoperative platinum based chemotherapy is associated with a small benefit in progression-free survival and overall survival irrespective of radiotherapy treatment, and could be an alternative to radiotherapy and has added value when used with radiotherapy.
BGCS uterine cancer guidelines: Recommendations for practice.
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.
TLDR
The results of this meta-analysis provide the most reliable estimates of the relative survival benefits of IP over IV therapy and should be used as part of the decision making process.
...
1
2
3
4
5
...